From: Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement
Variables | Hazard ratio (95% CI) | P value |
---|---|---|
Age | 1.043 (0.906–1.083) | 0.091 |
Male | 1.052 (0.922–1.074) | 0.106 |
Smoking | 1.078 (1.003–1.125) | 0.015 |
HTN | 1.106 (1.018–1.276) | 0.021 |
DM | 1.145 (1.056–1.303) | 0.007 |
Family history | 1.008 (0.914–1.022) | 0.108 |
BMI | 1.002 (0.967–1.005) | 0.455 |
CHOL | 1.089 (0.953–1.117) | 0.075 |
LDL-C | 1.227 (1.104–1.420) | <0.001 |
HDL-C | 0.895 (0.806–1.007) | 0.303 |
TG | 1.007 (0.926–1.011) | 0.436 |
Lp (a) | 1.103 (1.048–1.166) | 0.014 |
CREA | 1.012 (0.915–1.017) | 0.344 |
BUN | 1.005 (0.933–1.009) | 0.428 |
Uric acid | 1.017 (0.908–1.032) | 0.447 |
Hs-CRP | 1.168 (1.109–1.254) | <0.001 |
Lp-PLA2 | 1.233 (1.114–1.387) | <0.001 |
LVEF | 1.017 (0.908–1.032) | 0.160 |
FS | 1.011 (0.933–1.019) | 0.174 |
Anti-platelet | 0.826 (0.801–0.944) | 0.022 |
Statins | 0.778 (0.723–0.806) | <0.001 |
Medications for HTN | 0.909 (0.886–1.005) | 0.096 |
Medications for DM | 0.845 (0.817–0.896) | 0.018 |